Ngwane E, Bower B
Arch Dis Child. 1980 Mar;55(3):171-4. doi: 10.1136/adc.55.3.171.
Of the 265 children aged between 6 and 18 months admitted to hospital in a 26-month period each with his first febrile convulsion, there were 64 who satisfied our criteria for a simple febrile convulsion. Of these, 43 (random) were entered into a double-blind trial of continuous sodium valproate versus phenobarbitone, and 21 were untreated. The dosage was phenobarbitone 3-6 mg/kg per day; sodium valproate 30-60 mg/kg per day. 39 completed treatment (21 phenobarbitone, 18 sodium valproate), 2 in each group being withdrawn because of unacceptable side effects. Close supervision and random serum drug estimations showed compliance to be good. After a mean treatment period of 12 months (mean age 25 months) there had been one recurrence in the sodium valproate group compared with 7 in the untreated group (P less than 0.05), and 4 recurrences in the phenobarbitone group. The difference between treatment and no treatment was significant (P less than 0.05). These results suggest that in simple febrile convulsions occurring between 6 and 18 months of age sodium valproate is as effective as phenobarbitone in preventing recurrence and that either treatment is better than none.
在26个月期间，共有265名6至18个月大的儿童因首次热性惊厥入院，其中64名符合我们对单纯性热性惊厥的标准。在这些儿童中，43名（随机选取）进入了丙戊酸钠持续给药与苯巴比妥的双盲试验，21名未接受治疗。剂量为苯巴比妥每日3 - 6毫克/千克；丙戊酸钠每日30 - 60毫克/千克。39名完成治疗（21名使用苯巴比妥，18名使用丙戊酸钠），每组各有2名因出现无法接受的副作用而退出。密切监测和随机血清药物测定显示依从性良好。平均治疗期为12个月（平均年龄25个月）后，丙戊酸钠组有1例复发，未治疗组有7例复发（P小于0.05），苯巴比妥组有4例复发。治疗与未治疗之间的差异具有统计学意义（P小于0.05）。这些结果表明，对于6至18个月大儿童发生的单纯性热性惊厥，丙戊酸钠在预防复发方面与苯巴比妥效果相当，且两种治疗方法都比不治疗要好。
